Neutral
Outlook Therapeutics is selling 8,539,709 shares of common stock at $0.5855 per share to a single institutional investor and will amend existing warra...
Bullish
Outlook Therapeutics has announced that the FDA's office of new drugs has granted its appeal in the formal dispute resolution process for ONS-5010/Lyt...
Bullish
Outlook Therapeutics (NASDAQ:OTLK) shares surged 50% after the company successfully appealed an FDA decision regarding its drug LYTENAVA for neovascul...
Bullish
Outlook Therapeutics (OTLK) received FDA appeal approval for Lytenava, its treatment for neovascular age-related macular degeneration (nAMD), and plan...
Outlook Therapeutics Inc. has entered into an At-The-Market (ATM) offering agreement with H.C. Wainwright for up to $100 million. This financial move ...